CN105713046A - 一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法 - Google Patents
一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法 Download PDFInfo
- Publication number
- CN105713046A CN105713046A CN201610070277.0A CN201610070277A CN105713046A CN 105713046 A CN105713046 A CN 105713046A CN 201610070277 A CN201610070277 A CN 201610070277A CN 105713046 A CN105713046 A CN 105713046A
- Authority
- CN
- China
- Prior art keywords
- drug
- preparation
- platinum
- hydrogel
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 239000000017 hydrogel Substances 0.000 title claims abstract description 39
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 33
- 229940002612 prodrug Drugs 0.000 title claims abstract description 30
- 239000000651 prodrug Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title abstract description 19
- 239000000178 monomer Substances 0.000 claims abstract description 19
- 239000004005 microsphere Substances 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003381 stabilizer Substances 0.000 claims abstract description 12
- 150000008064 anhydrides Chemical class 0.000 claims abstract description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 19
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 15
- 229960004316 cisplatin Drugs 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 11
- 229910021641 deionized water Inorganic materials 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 8
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 8
- 229940043265 methyl isobutyl ketone Drugs 0.000 claims description 8
- 150000003057 platinum Chemical class 0.000 claims description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 7
- 239000003999 initiator Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 7
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical group N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical group CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 3
- 190014017285 Satraplatin Chemical compound 0.000 claims description 3
- XJXKGUZINMNEDK-GPJOBVNKSA-L [(4r,5r)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](CN)[C@@H](CN)O1 XJXKGUZINMNEDK-GPJOBVNKSA-L 0.000 claims description 3
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 claims description 3
- FKCBLVCOSCZFHV-UHFFFAOYSA-N acetonitrile;ethanol Chemical compound CCO.CC#N FKCBLVCOSCZFHV-UHFFFAOYSA-N 0.000 claims description 3
- HXYXTCJDWHHCBW-UHFFFAOYSA-N acetonitrile;toluene Chemical compound CC#N.CC1=CC=CC=C1 HXYXTCJDWHHCBW-UHFFFAOYSA-N 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 229950006835 eptaplatin Drugs 0.000 claims description 3
- -1 iproplatin Chemical compound 0.000 claims description 3
- 229950010897 iproplatin Drugs 0.000 claims description 3
- 229950008991 lobaplatin Drugs 0.000 claims description 3
- VLCAYQIMSMPEBW-UHFFFAOYSA-N methyl 3-hydroxy-2-methylidenebutanoate Chemical compound COC(=O)C(=C)C(C)O VLCAYQIMSMPEBW-UHFFFAOYSA-N 0.000 claims description 3
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 3
- 229950008017 ormaplatin Drugs 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 229960005399 satraplatin Drugs 0.000 claims description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 2
- HTOBCWQYHHELFE-UHFFFAOYSA-N acetonitrile oxolane Chemical compound O1CCCC1.O1CCCC1.C(C)#N HTOBCWQYHHELFE-UHFFFAOYSA-N 0.000 claims description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- NJSUFZNXBBXAAC-UHFFFAOYSA-N ethanol;toluene Chemical compound CCO.CC1=CC=CC=C1 NJSUFZNXBBXAAC-UHFFFAOYSA-N 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical group [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 claims description 2
- ARJOQCYCJMAIFR-UHFFFAOYSA-N prop-2-enoyl prop-2-enoate Chemical compound C=CC(=O)OC(=O)C=C ARJOQCYCJMAIFR-UHFFFAOYSA-N 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 241000233803 Nypa Species 0.000 claims 1
- 235000005305 Nypa fruticans Nutrition 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 12
- 229960003180 glutathione Drugs 0.000 abstract description 9
- 108010024636 Glutathione Proteins 0.000 abstract description 5
- 239000003937 drug carrier Substances 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 235000003969 glutathione Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000018734 Sambucus australis Nutrition 0.000 description 1
- 244000180577 Sambucus australis Species 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229920001562 poly(N-(2-hydroxypropyl)methacrylamide) Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于生物医药技术领域,具体为一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法。本发明的前体药物是利用抗肿瘤的铂类药物经双氧水氧化为Pt(IV)的六配体配合物,再与含有双键的酸酐或羧酸反应得到。该前体药物可以自聚合,或和其他亲水性单体共聚,制备高载药量的药物微球。该微球粒径均匀,大小可调控,通过使用稳定剂可以在水溶液中保持长期的稳定性。本发明制备工艺简洁,得到的纳米水凝胶药物载体具有谷胱甘肽刺激响应性,使得纳米水凝胶在肿瘤细胞外低谷胱甘肽浓度的环境中保持稳定,长时间循环,很少泄露药物,而在肿瘤细胞内还原性环境中快速降解,变为小分子量的线性链,快速释放药物,从而实现对目标肿瘤细胞的靶向杀伤作用。
Description
技术领域
本发明属于生物医药技术领域,具体涉及一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法。
背景技术
由于癌症对人类生命健康的极大威胁,抗癌药物的研究一直广受关注。顺铂也称顺式二氯二氨合铂(Cisplatin,Pt(NH3)2Cl2),是一种非细胞周期特异性的抗癌药物,具有细胞毒性,能与DNA双螺旋上的鸟嘌呤的N7氮原子结合,形成稳定的交联结构,从而破坏DNA的复制功能,导致细胞凋亡。自从1967年人们发现顺铂的抗癌活性以来,铂类金属抗癌药物的研究和应用得到了极大的发展,除顺铂外,还有一系列具有类似结构和功能的顺铂衍生物,如卡铂、奥沙利铂、赛特铂、奥马铂、异丙铂、乐铂、庚铂以及其他含有单个或多个铂原子的的抗癌药物。这种铂类药物具有抗癌谱广,作用强且无交叉耐药性,尤其对于睾丸癌、卵巢癌有很好的疗效。然而,铂类药物存在毒副作用大,溶解性差,在人体内易于和血浆蛋白结合,尤其容易受到含巯基蛋白质(血清蛋白质等)的攻击,从而失去抗癌活性,所以临床效果往往有限。近年来研究发现四价铂配合物(Pt(IV))相对于常用的二价铂配合物(Pt(II))而言,由于在垂直的轴向上增加了两个配体,形成八面体结构,因而具有较低的反应活性和毒副作用。而在药物进入肿瘤细胞后,由于细胞内部的还原性环境,使得迅速转化为具有细胞毒性的Pt(II)结构,从而具有针对性的对肿瘤细胞产生杀伤作用。然而,四价铂配合物(Pt(IV))作为小分子药物,在人体内同样存在循环时间短,代谢速度快,靶向性差的特点,很难在肿瘤部位得到有效的富集,将其运输至肿瘤组织部位仍然是一个很大的挑战。
本发明针对铂类药物的以上特点,对四价铂配合物(Pt(IV))轴向上的羟基进行了修饰,从而第一次得到带有两个双键的新型结构,该铂类抗肿瘤前体药物在有机溶剂中可以自身聚合,也可以与其他单体共聚,形成粒径均一的纳米粒子。通过利用生物相容性的稳定剂对粒子表面进行简单的修饰,使其能够在生物体内保持良好的稳定性,增加长循环时间,在肿瘤细胞内部还原性的条件下可使得微球降解,从而释放出铂类药物。另一方面,稳定剂的外部也可以修饰相应的靶向分子(如叶酸、环RGD肽、转铁蛋白等),从而使其在肿瘤部位得到有效的富集。
发明内容
本发明的目的在于提供一种铂类抗肿瘤前体药物,其纳米水凝胶微球及其制备方法;同时,提供上述纳米水凝胶在肿瘤治疗中的应用。
本发明提供的铂类抗肿瘤前体药物的制备方法,具体步骤如下:将二价的铂类药物与双氧水在避光条件下65-75℃(优选70℃)反应10-12h,得到轴向双羟基配位的四价铂配合物Pt(IV)-(OH)2,产物通过旋蒸除去部分溶剂,过滤后真空烘干,再与含有双键的酸酐或羧酸在避光条件下55-65℃(优选60℃)反应12~24h,得到轴向具有两个双键的铂(IV)类抗肿瘤前体药物。
其中,所述二价的铂类药物可以是顺铂、卡铂、奥沙利铂、赛特铂、奥马铂、异丙铂、乐铂或庚铂等。
其中,所述的酸酐可以为甲基丙烯酸酐、丙烯酸酐、马来酸酐;其中羧酸可以为丙烯酸、甲基丙烯酸、马来酸或富马酸。
其中,所述铂类药物与双氧水的重量比例为1:1~1:10,Pt(IV)-(OH)2与酸酐或羧酸的重量比例为1:1~1:5。
本发明提供的铂类前体药物的水凝胶微球的制备方法,具体步骤为:在有机溶剂中加入亲水性单体,以上述铂类抗肿瘤药物前药作为交联剂,在引发剂的存在下,加热进行反应,反应温度为50~120℃;用蒸馏沉淀法除去一半溶剂,回流溶剂反应时间为0.2~4h;再用离心法除去剩下溶剂和未反应单体,用乙醇和去离子水反复洗涤3-5次;然后在真空烘箱内30~55℃干燥5~24h,即得到纳米水凝胶粒子。
本发明中,所述有机溶剂为单一的乙腈、乙醇、水、四氢呋喃、甲基异丁基酮或甲苯等溶剂;或者为乙腈-乙醇、乙腈-四氢呋喃、乙腈-水、乙腈-甲苯、乙醇-甲苯或甲基异丁基酮-乙腈等的混合溶剂。
本发明中,所述的亲水性单体为甲基丙烯酸(MAA)、丙烯酸(AA)、甲基丙烯酸羟乙酯(HEMA)、丙烯酰胺(AM)、N-异丙基丙烯酰胺(NIPAM)或N-2-羟丙基甲基丙烯酰胺(HPMA)等单体。
本发明中,所述引发剂为偶氮二异丁腈(AIBN)或过氧化二苯甲酰(BPO)等。
本发明中,所述单体在单一或混合溶剂中的浓度为0.5wt%~20.0wt%。
本发明中,所述单体与前体药物的重量比例为10:1~0:1,优选两者比例为10:1~0.5:1。
本发明所制备的上述纳米水凝胶粒子的粒径为50-950nm,多分散度为0.04-0.16。
上述制备的纳米水凝胶,可以进一步与双亲性的稳定剂相互组装,从而提高其在生理环境中的稳定性和体内的长循环过程。具体操作步骤如下:
将上述制得的纳米水凝胶粒子分散在少量去离子水中,磁力搅拌下缓慢滴入溶解有稳定剂的水溶液中,并超声分散15-20min,这一过程中稳定剂的疏水部分通过非共价疏水作用与纳米粒子交联网络结合,亲水部分伸展在纳米粒子外部,从而实现良好的稳定作用。
所述稳定剂可以是TPGS1000、F127、PVA、PLGA-PEG、DSPE-PEG等。
本发明制得的上述纳米水凝胶作为纳米药物,可对体内的肿瘤组织进行有效的杀伤。其特点在于,纳米药物在正常血液和组织循环中能够保持药物良好的药物密封作用,从而使药物不会释放出来伤害正常的组织和细胞,通过高通透性和滞留效应(EPReffect)富集在肿瘤组织后,纳米粒子被肿瘤细胞吞噬,细胞内的还原性环境使得顺铂药物得以快速的释放出来,从而对肿瘤细胞有针对性的杀伤作用。
本发明中,降解的测试条件为:在25mL的单口烧瓶里加入5mg的纳米水凝胶粒子,分别加入10mL的三种缓冲溶液中(磷酸盐缓冲溶液pH=7.4、6.0,醋酸盐缓冲溶液pH=5.0,然后加入不同浓度的谷胱甘肽、半胱氨酸或抗坏血酸,放入恒温摇床(200rpm摇速,37.5℃)匀速振荡。并在不同时间取点测试分散液的浊度变化。
释药的条件为:将10mg载药纳米水凝胶粒子分散在10mL的两种缓冲溶液中(磷酸盐缓冲溶液,pH=7.4;醋酸盐缓冲溶液,pH=5.0),超声分散均匀,然后分为5份,每份2mL,将一份凝胶溶液移入透析袋中(透析分子量Mn=14000),再放入80mL的含不同浓度的谷胱甘肽的缓冲溶液中,即刻开始计时释药。在预订时间,从瓶内取出3mL释药的缓冲溶液进行紫外测量,再补充3mL纯的缓冲溶液保持体积恒定。
所制备的纳米水凝胶在还原剂降解后,分子量小于2000且分子量分布均匀(Mn=761,PDI<1.2),远小于代谢阈值(45-50kDa),可以很好的代谢排出体外。
本发明中,所述的水凝胶纳米药物,由铂类抗肿瘤药物交联聚合形成,其载药率可以方便地用前体药物和共聚单体的不同比例聚合反应加以控制。在上述方案的基础上,所属抗癌药物顺铂的载药率的重量百分比最高可达63.8%。
顺铂的释放过程可以通过调节环境的谷胱甘肽浓度和pH值加以控制,在高谷胱甘肽浓度和较低pH值条件下(模拟细胞内环境)展现出较快的释放速度,而在低谷胱甘肽浓度和中性的pH值条件下(模拟细胞外环境)保持稳定,释放量小于5%。
本发明中,通过将上述纳米药物和人卵巢癌细胞SKOV-3一起培养进行细胞实验,纳米水凝胶药物载体体现出了很好的释药行为。通过荧光显微镜进行观察,发现5h后载药纳米水凝胶粒子已经进入细胞,24h后顺铂药物对于细胞的杀伤作用已经非常明显,细胞存活率大幅降低,剩余的少量细胞也处于皱缩状态,说明所制备的纳米水凝胶是一种较好的药物载体。
本发明优点在于制备工艺清晰简洁,得到的纳米水凝胶药物载体具有谷胱甘肽刺激响应性,谷胱甘肽响应性可以使得纳米水凝胶在肿瘤细胞外低谷胱甘肽浓度的环境中保持稳定,长时间循环,很少泄露药物,而在肿瘤细胞内高谷胱甘肽浓度的环境中快速降解,变为小分子量的线性链,从而快速释放药物,达到在目标肿瘤细胞内控制释放抗癌药物的效果,体现出与谷胱甘肽的协同效应。而凝胶粒子的可生物降解性和降解后的小分子量又可以使得药物载体迅速代谢排出体外,进一步减少对人体的副作用。
附图说明
图1:顺铂前体药物纳米水凝胶微球的透射电镜照片。
图2:顺铂前体药物纳米水凝胶微球的宫颈癌细胞SKOV-3毒性实验(24h)。
具体实施方式
下面将通过实例进一步对本发明进行描述,但不限于这些实施例。
实施例1:顺铂类抗肿瘤前体药物的制备
在100ml的三口圆底烧瓶中加入顺铂2g,去离子水50ml和过氧化氢(30%)11.4ml,在氮气气氛下,70℃避光反应6h后降至室温再反应12h,旋蒸掉部分水后冰水冷却析出产物,抽滤,用冰水、乙醇、乙醚一次洗涤反应产物后真空干燥,得到轴向两端羟基修饰的Pt(IV)前驱体,记做Pt(IV)-(OH)2-1。
取上述2g前驱体Pt(IV)-(OH)2-1加入到50ml三口圆底烧瓶中,然后加入与其摩尔比为1:2的甲基丙烯酸酐和10ml预先干燥的二甲基亚砜(DMSO),在氮气气氛和60℃避光下反应24h,反应后冷冻干燥除去溶剂,产物用乙醚和丙酮重结晶,干燥,得到两端双键修饰的Pt(IV)交联剂,记做Pt(IV)-1。
实施例2:奥沙利铂类抗肿瘤前体药物的制备
在100ml的三口圆底烧瓶中加入奥沙利铂2g,去离子水50ml和过氧化氢(30%)11.4ml,在氮气气氛下,70℃避光反应6h后降至室温再反应12h,旋蒸掉部分水后冰水冷却析出产物,抽滤,用冰水、乙醇、乙醚一次洗涤反应产物后真空干燥,得到轴向两端羟基修饰的Pt(IV)前驱体,记做Pt(IV)-(OH)2-2
取上述2g前驱体Pt(IV)-(OH)2-1加入到50ml三口圆底烧瓶中,然后加入与其摩尔比为1:2的甲基丙烯酸酐和10ml预先干燥的二甲基亚砜(DMSO),在氮气气氛和60℃避光下反应24h,反应后冷冻干燥除去溶剂,产物用乙醚和丙酮重结晶,干燥,得到两端双键修饰的Pt(IV)交联剂,记做Pt(IV)-2。
实施例3:奥沙利铂类抗肿瘤前体药物纳米水凝胶微球的制备
MAA单体400mg,ZDMA交联剂100mg,AIBN引发剂16.7mg,乙腈40mL,加热到95℃,回流溶剂反应2小时,离心除去溶剂和未反应单体,用乙醇和去离子水洗涤3次,真空烘箱干燥24h。
实施例4:顺铂类抗肿瘤前体药物纳米水凝胶微球的制备
AA单体400mg,Pt(IV)-1交联剂100mg,15.3mgBPO引发剂,40mL乙腈-乙醇混合溶剂(V乙腈:V乙醇=1:1),加热到95℃,回流溶剂反应2小时,离心除去溶剂和未反应单体,用丙酮和去离子水洗涤3次,真空烘箱干燥24h。
实施例5:奥沙利铂前体药物交联的PMAA-co-PHPMA纳米水凝胶的制备
MAA单体200mg,HPMA200mg,Pt(IV)-2交联剂100mg,16.7mgAIBN引发剂,40mL乙腈-甲苯混合溶剂(V乙腈:V甲苯=4:1),加热到95℃,回流溶剂反应2小时,离心除去溶剂和未反应单体,用丙酮和去离子水洗涤3次,真空烘箱干燥24h。
实施例6:稳定剂TPGS1000稳定的铂交联纳米水凝胶制备
将顺铂类抗肿瘤前体药物纳米水凝胶微球均匀分散于0.5ml的去离子水中,在磁力搅拌的条件下缓慢滴加于TPGS1000的水溶液中,之后超声15min后,用去离子水离心洗涤3次,得到TPGS1000稳定的铂交联纳米水凝胶。
本发明制备的上述纳米水凝胶微,球粒径均匀,形态规整,大小可调控,通过使用稳定剂稳定之后可以在水溶液中保持长期的稳定性。另一方面,交联键合的Pt(IV)配合物易于在还原性的条件下被还原成Pt(II),从而导致微球的交联骨架解体,并快速释放出铂类药物分子。本发明能够使铂类抗肿瘤药物在不依赖载体的情况下自身交联成纳米粒子,从而运输至肿瘤部位,并在肿瘤细胞内的还原性氛围下进行Pt(IV)→Pt(II)的转化,使轴向的两个羟基断裂,交联键打开使药物被定向的释放于肿瘤细胞内部,从而实现无载体的高载药模式,降低辅料浓度以及药物在正常组织和细胞的毒副作用。
Claims (10)
1.一种铂类抗肿瘤前体药物的制备方法,其特征在于,具体步骤如下:将二价的铂类药物与双氧水在避光条件下65-75℃反应10-12h,得到轴向双羟基配位的四价铂配合物Pt(IV)-(OH)2,产物通过旋蒸除去部分溶剂,过滤后真空烘干,再与含有双键的酸酐或羧酸在避光条件下55-65℃反应12~24h,得到轴向具有两个双键的铂(IV)类抗肿瘤前体药物;
所述二价的铂类药物为顺铂、卡铂、奥沙利铂、赛特铂、奥马铂、异丙铂、乐铂或庚铂;
所述的酸酐为甲基丙烯酸酐、丙烯酸酐、马来酸酐;所述羧酸为丙烯酸、甲基丙烯酸、马来酸或富马酸;
铂类药物与双氧水的重量比例为1:1~1:10,Pt(IV)-(OH)2与酸酐或羧酸的重量比例为1:1~1:5。
2.一种由权利要求1所述制备方法制备得到的铂类抗肿瘤前体药物。
3.一种基于权利要求2所述铂类抗肿瘤前体药物的水凝胶微球的制备方法,其特征在于,具体步骤为:在有机溶剂中加入亲水性单体,以所述铂类抗肿瘤药物前药作为交联剂,在引发剂的存在下,加热进行反应,反应温度为50~120℃;用蒸馏沉淀法除去一半溶剂,回流溶剂反应时间为0.2~4h;再用离心法除去剩下溶剂和未反应单体,用乙醇和去离子水反复洗涤3-5次;然后在真空烘箱内30~55℃干燥5~24h,即得到纳米水凝胶粒子。
4.根据权利要求3所述的制备方法,其特征在于,所述溶剂为乙腈、乙醇、水、四氢呋喃、甲基异丁基酮或甲苯单一的溶剂;或者为乙腈-乙醇、乙腈-四氢呋喃、乙腈-水、乙腈-甲苯、乙醇-甲苯或甲基异丁基酮-乙腈的混合溶剂。
5.根据权利要求3所述的制备方法,其特征在于,所述的亲水性单体为甲基丙烯酸、丙烯酸、甲基丙烯酸羟乙酯、丙烯酰胺、N-异丙基丙烯酰胺或N-2-羟丙基甲基丙烯酰胺;所述引发剂为偶氮二异丁腈或过氧化二苯甲酰。
6.根据权利要求4所述的制备方法,其特征在于,所述单体在单一或混合溶剂中的浓度为0.5wt%~20.0wt%。
7.根据权利要求3所述的制备方法,其特征在于,所述单体与铂类抗肿瘤药物前药的重量比例为10:1~0.5:1。
8.根据权利要求3所述的制备方法,其特征在于,所述纳米水凝胶粒子的粒径为50-950nm,多分散度为0.04-0.16。
9.由权利要求3-8之一所述制备方法制备得到的基于铂类抗肿瘤前体药物的水凝胶微球药物。
10.一种提高权利要求9所述的基于铂类抗肿瘤前体药物的水凝胶微球药物稳定性的方法,其特征在于,具体步骤如下:将所述的水凝胶微球药物分散在去离子水中,磁力搅拌下缓慢滴入溶解有稳定剂的水溶液中,并超声分散15-20min,这一过程中稳定剂的疏水部分通过非共价疏水作用与纳米粒子交联网络结合,亲水部分伸展在纳米粒子外部,从而实现良好的稳定作用;其中,所述稳定剂是TPGS1000、F127、PVA、PLGA-PEG或DSPE-PEG。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610070277.0A CN105713046B (zh) | 2016-02-01 | 2016-02-01 | 一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610070277.0A CN105713046B (zh) | 2016-02-01 | 2016-02-01 | 一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105713046A true CN105713046A (zh) | 2016-06-29 |
CN105713046B CN105713046B (zh) | 2018-10-26 |
Family
ID=56154636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610070277.0A Expired - Fee Related CN105713046B (zh) | 2016-02-01 | 2016-02-01 | 一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105713046B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106267229A (zh) * | 2016-08-12 | 2017-01-04 | 南开大学 | 一种肝靶向载铂纳米前药的结构及其制备方法 |
CN106619568A (zh) * | 2016-12-09 | 2017-05-10 | 浙江大学 | 一种铂纳米晶复合纳米材料的制备方法及产品 |
CN106946946A (zh) * | 2017-03-29 | 2017-07-14 | 昆明贵研药业有限公司 | 一种铂类抗肿瘤药物米铂氧化物的制备方法 |
CN108144067A (zh) * | 2017-12-27 | 2018-06-12 | 安徽大学 | 四价铂化合物-双环双键两亲性聚合物前药、其纳米胶束及制备方法和应用 |
CN110898229A (zh) * | 2019-12-16 | 2020-03-24 | 福州大学 | 一种用于癌症协同治疗的双响应纳米前药的制备方法 |
CN113209131A (zh) * | 2021-04-25 | 2021-08-06 | 陕西科技大学 | 一种有机-无机双药杂化抗肿瘤分子、制备方法及其应用 |
CN114939102A (zh) * | 2022-05-26 | 2022-08-26 | 国科温州研究院(温州生物材料与工程研究所) | 一种铂前药诱导光交联水凝胶的制备方法及应用 |
CN117050113A (zh) * | 2023-07-17 | 2023-11-14 | 南方医科大学南方医院 | 一种四价铂类纳米药物颗粒的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4482569A (en) * | 1980-01-03 | 1984-11-13 | Nederlandse Centrale Organisatie Voor Toegepastnatuurweten-Schappelijk Onderzoek | Platinum (IV)-diamine complexes, a process for the preparation of pharmaceutical compositions and a method of treating malignant tumors in mice |
EP0328274A1 (en) * | 1988-02-02 | 1989-08-16 | Johnson Matthey, Inc., | Pt (IV) complexes |
CN104353083A (zh) * | 2014-11-14 | 2015-02-18 | 复旦大学 | 一种含有铂类抗肿瘤药物的热致凝胶缓释注射剂及其制备方法 |
-
2016
- 2016-02-01 CN CN201610070277.0A patent/CN105713046B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4482569A (en) * | 1980-01-03 | 1984-11-13 | Nederlandse Centrale Organisatie Voor Toegepastnatuurweten-Schappelijk Onderzoek | Platinum (IV)-diamine complexes, a process for the preparation of pharmaceutical compositions and a method of treating malignant tumors in mice |
EP0328274A1 (en) * | 1988-02-02 | 1989-08-16 | Johnson Matthey, Inc., | Pt (IV) complexes |
CN104353083A (zh) * | 2014-11-14 | 2015-02-18 | 复旦大学 | 一种含有铂类抗肿瘤药物的热致凝胶缓释注射剂及其制备方法 |
Non-Patent Citations (4)
Title |
---|
AMPARO ALVAREZ-VALDE´S等: "Preparation and Characterization of Platinum(II) and (IV) Complexes of 1,3-Diaminepropane and 1,4-Diaminebutane: Circumvention of Cisplatin Resistance and DNA Interstrand Cross-Link Formation in CH1cisR Ovarian Tumor Cells", 《J. MED. CHEM.》 * |
ELISABETTA GABANO等: "Pros and cons of bifunctional platinum(IV) antitumor prodrugs: two are (not always) better than one", 《DALTON TRANS.》 * |
MICHAEL GROESSL等: "Anticancer metallodrug research analytically painting the"omics"picture—current developments and future trends", 《ANAL BIOANAL CHEM》 * |
MICHAEL R. REITHOFER等: "Unprecedented twofold intramolecular hydroamination in diam(m)ine dicarboxylatodichloridoplatinum(IV) complexes – ethane-1,2-diaminevs. ammine ligands", 《CHEM. COMMUN.》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106267229B (zh) * | 2016-08-12 | 2019-09-10 | 南开大学 | 一种肝靶向载铂纳米前药的结构及其制备方法 |
CN106267229A (zh) * | 2016-08-12 | 2017-01-04 | 南开大学 | 一种肝靶向载铂纳米前药的结构及其制备方法 |
CN106619568A (zh) * | 2016-12-09 | 2017-05-10 | 浙江大学 | 一种铂纳米晶复合纳米材料的制备方法及产品 |
CN106619568B (zh) * | 2016-12-09 | 2020-01-17 | 浙江大学 | 一种铂纳米晶复合纳米材料的制备方法及产品 |
CN106946946A (zh) * | 2017-03-29 | 2017-07-14 | 昆明贵研药业有限公司 | 一种铂类抗肿瘤药物米铂氧化物的制备方法 |
CN108144067B (zh) * | 2017-12-27 | 2020-11-24 | 安徽大学 | 四价铂化合物-双环双键两亲性聚合物前药、其纳米胶束及制备方法和应用 |
CN108144067A (zh) * | 2017-12-27 | 2018-06-12 | 安徽大学 | 四价铂化合物-双环双键两亲性聚合物前药、其纳米胶束及制备方法和应用 |
CN110898229A (zh) * | 2019-12-16 | 2020-03-24 | 福州大学 | 一种用于癌症协同治疗的双响应纳米前药的制备方法 |
CN110898229B (zh) * | 2019-12-16 | 2021-07-13 | 福州大学 | 一种用于癌症协同治疗的双响应纳米前药的制备方法 |
CN113209131A (zh) * | 2021-04-25 | 2021-08-06 | 陕西科技大学 | 一种有机-无机双药杂化抗肿瘤分子、制备方法及其应用 |
CN114939102A (zh) * | 2022-05-26 | 2022-08-26 | 国科温州研究院(温州生物材料与工程研究所) | 一种铂前药诱导光交联水凝胶的制备方法及应用 |
CN114939102B (zh) * | 2022-05-26 | 2023-10-10 | 国科温州研究院(温州生物材料与工程研究所) | 一种铂前药诱导光交联水凝胶的制备方法及应用 |
CN117050113A (zh) * | 2023-07-17 | 2023-11-14 | 南方医科大学南方医院 | 一种四价铂类纳米药物颗粒的制备方法 |
CN117050113B (zh) * | 2023-07-17 | 2024-03-19 | 南方医科大学南方医院 | 一种四价铂类纳米药物颗粒的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105713046B (zh) | 2018-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105713046A (zh) | 一种铂类抗肿瘤前体药物,其纳米水凝胶药物及其制备方法 | |
CN104177624B (zh) | 含二硫键与酰腙键的双重敏感两亲性三嵌段共聚物及其制备方法与应用 | |
CN110302175B (zh) | 一种含疏水空腔硫辛酸纳米胶囊及其制备方法和应用 | |
CN106139144A (zh) | 一种具有协同抗肿瘤特性的透明质酸修饰的金‑碳纳米球及其制备方法与应用 | |
Pérez et al. | pH and glutathion-responsive hydrogel for localized delivery of paclitaxel | |
CN104788670A (zh) | 一种双响应性葡聚糖-聚氨基酸嵌段共聚物及其制备方法和载药胶束 | |
CN110063933B (zh) | 一种葡聚糖基纳米凝胶及其制备方法和应用 | |
CN104491871A (zh) | 一种基于聚谷氨酸和胱胺的pH与还原敏感性的纳米微凝胶 | |
CN112546027B (zh) | 载脂溶性色素纳米粒及其制备方法 | |
CN108295046A (zh) | 一种白蛋白纳米颗粒的制备方法及制得的白蛋白纳米颗粒与应用 | |
Pornpitchanarong et al. | Synthesis of novel N-vinylpyrrolidone/acrylic acid nanoparticles as drug delivery carriers of cisplatin to cancer cells | |
CN104892949A (zh) | 一种谷胱甘肽/pH双重刺激响应离子交联型聚合物纳米水凝胶及其制备方法和应用 | |
CN110804178B (zh) | 一种具有谷胱甘肽响应性的纳米载药体系及其制备方法和应用 | |
CN104013968A (zh) | 一种叶酸修饰胆固醇疏水改性海藻酸钠自组装纳米粒及其制备方法和应用 | |
Yu et al. | ATP-triggered drug release system based on ZIF-90 loaded porous poly (lactic-co-glycolic acid) microspheres | |
Keshtmand et al. | Enhanced anticancer effect of Artemisia turcomanica extract in niosomal formation on breast cancer cells: in-vitro study | |
CN106606778A (zh) | 含磷酸胆碱聚合物包覆的核壳式磁性复合粒子及其制备方法 | |
CN106866902A (zh) | 一种可降解双响应聚合物及其负载药物和金纳米粒子胶束的制备方法与应用 | |
Kamboj et al. | Preparation and characterization of metformin loaded Stearic Acid coupled F127 Nanoparticles | |
CN107126426B (zh) | 一种盐酸阿霉素自组装聚合物纳米粒及其制备方法 | |
CN109233820A (zh) | 一种g-C3N4量子点及其制备方法和应用 | |
CN103961713A (zh) | 一种壳聚糖修饰的介孔二氧化硅基缓控释材料的应用 | |
Das et al. | Formulation and in vitro evaluation of poly-(D, L-lactide-co-glycolide)(PLGA) nanoparticles of ellagic acid and its effect on human breast cancer, MCF-7 cell line | |
CN103239410B (zh) | 荧光及热/pH敏感的有机-无机复合微球载体的制备方法 | |
CN109223711A (zh) | 薄膜水化法控制莪术醇衍生物peg-pla胶束粒径的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181026 Termination date: 20210201 |